NO308022B1 - Sammensetninger for orale preparater - Google Patents

Sammensetninger for orale preparater

Info

Publication number
NO308022B1
NO308022B1 NO943341A NO943341A NO308022B1 NO 308022 B1 NO308022 B1 NO 308022B1 NO 943341 A NO943341 A NO 943341A NO 943341 A NO943341 A NO 943341A NO 308022 B1 NO308022 B1 NO 308022B1
Authority
NO
Norway
Prior art keywords
pct
composition
date sep
oral preparations
sec
Prior art date
Application number
NO943341A
Other languages
English (en)
Norwegian (no)
Other versions
NO943341L (no
NO943341D0 (no
Inventor
Toshio Yajima
Nobuo Umeki
Hidefumi Hayashi
Ikuo Koyama
Kuniaki Ishii
Shigeru Itai
Kimihide Shimano
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of NO943341L publication Critical patent/NO943341L/no
Publication of NO943341D0 publication Critical patent/NO943341D0/no
Publication of NO308022B1 publication Critical patent/NO308022B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
NO943341A 1992-03-12 1994-09-09 Sammensetninger for orale preparater NO308022B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5344292 1992-03-12
JP21990492 1992-08-19
PCT/JP1993/000291 WO1993017667A1 (en) 1992-03-12 1993-03-10 Composition for oral preparations

Publications (3)

Publication Number Publication Date
NO943341L NO943341L (no) 1994-09-09
NO943341D0 NO943341D0 (no) 1994-09-09
NO308022B1 true NO308022B1 (no) 2000-07-10

Family

ID=26394153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943341A NO308022B1 (no) 1992-03-12 1994-09-09 Sammensetninger for orale preparater

Country Status (12)

Country Link
US (1) US5707646A (es)
EP (1) EP0630233B1 (es)
JP (1) JP3265680B2 (es)
AT (1) ATE143258T1 (es)
AU (1) AU670428B2 (es)
CA (1) CA2131547C (es)
DE (1) DE69305069T2 (es)
ES (1) ES2095043T3 (es)
FI (1) FI109657B (es)
MX (1) MXPA93001352A (es)
NO (1) NO308022B1 (es)
WO (1) WO1993017667A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0168715B1 (ko) * 1992-11-30 1999-01-15 밋첼 아이. 커시너 맛을 차단하는 약제학적 조성물
MX9603480A (es) * 1994-02-16 1997-12-31 Abbott Lab Procedimiento para preparar formulaciones farmaceuticas en particulas finas.
US5728403A (en) * 1994-10-05 1998-03-17 The Board Of Regents Of The University Of Nebraska Coating technology for taste masking orally administered bitter drugs
DE29502547U1 (de) * 1995-02-16 1995-03-30 Röhm GmbH, 64293 Darmstadt Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
AU694655B2 (en) * 1995-05-02 1998-07-23 Taisho Pharmaceutical Co., Ltd. Composition for oral administration
AUPO637197A0 (en) * 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
DE19617487A1 (de) † 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DE19706978A1 (de) * 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
DE19706979A1 (de) * 1997-02-21 1998-08-27 Lindopharm Gmbh Kombinationspräparat für oral applizierbare Erythromycine
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
JP3466921B2 (ja) * 1998-06-03 2003-11-17 大塚製薬株式会社 味マスキング医薬製剤
AU5997999A (en) * 1998-09-30 2000-04-17 Taisho Pharmaceutical Co., Ltd. Grains for oral preparations
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
CA2367373C (en) * 1999-03-17 2011-09-20 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions
SI20244A (sl) * 1999-05-19 2000-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Granulacija v talini
IN191239B (es) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
AU2001225787C1 (en) * 2000-02-29 2006-09-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
MXPA02009587A (es) * 2000-03-28 2003-05-14 Biochemie Gmbh Particulas granuladas con sabor enmascarado.
PT1276470E (pt) 2000-04-20 2007-08-13 Novartis Ag Composição de revestimento para dissimular o sabor
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
WO2001091761A1 (fr) * 2000-06-01 2001-12-06 Taisho Pharmaceutical Co.,Ltd. Matrices pour preparations orales
WO2002005786A1 (fr) * 2000-07-17 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Composition pharmaceutique a absorbabilite per os amelioree
RU2281757C2 (ru) * 2000-09-19 2006-08-20 Дайити Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
MXPA03003146A (es) * 2000-10-13 2004-12-06 Advancis Pharmaceuticals Derivados de eritromicina de liberacion prolongada.
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
AU2002224053A1 (en) * 2000-11-21 2002-06-03 Kyorin Pharmaceutical Co. Ltd. Dry syrup preparations
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
DK1411899T3 (da) * 2001-08-01 2009-06-02 Novartis Ag Smagsmaskerende sammensætning
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
MXPA05000977A (es) 2002-08-12 2005-05-16 Pfizer Prod Inc Composiciones farmaceuticas de farmacos semiordenados y polimeros.
ES2310676T3 (es) 2002-12-20 2009-01-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa.
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
KR100508992B1 (ko) * 2003-03-31 2005-08-17 한국유나이티드제약 주식회사 쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
JP2007502294A (ja) * 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
NZ546677A (en) * 2003-11-14 2008-11-28 Pfizer Prod Inc Solid amorphous dispersions of an MTP inhibitor for treatment of obesity
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
KR20080064209A (ko) * 2003-12-04 2008-07-08 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
JP2007513145A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
JP2007513937A (ja) * 2003-12-09 2007-05-31 ファイザー インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤を含む組成物
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
JP4779970B2 (ja) * 2004-06-03 2011-09-28 大正製薬株式会社 経口製剤およびその製造方法
AU2005269981A1 (en) * 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
WO2006082518A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
CN102026636B (zh) * 2008-03-31 2014-07-16 赛马拜制药公司 氧亚甲基芳基化合物和其用途
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
DE102009019268A1 (de) * 2009-04-28 2010-11-11 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit poröser Matrix
EP3520776A1 (en) 2009-06-16 2019-08-07 Pfizer Inc Dosage forms of apixaban
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
EP2585048B1 (en) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CR20160405A (es) 2014-03-17 2016-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US9867809B2 (en) 2015-06-30 2018-01-16 Kemin Industries, Inc. Encapsulated active ingredients for controlled enteric release
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
BR112019018688A2 (pt) 2017-03-10 2020-04-07 Pfizer derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
MX2021012491A (es) 2019-04-19 2022-01-24 Pfizer Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
US20220387402A1 (en) 2019-05-20 2022-12-08 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
KR20220123689A (ko) * 2020-03-11 2022-09-08 사와이세이야쿠 가부시키가이샤 과립 및 그것을 이용한 제제
AU2021289169B2 (en) 2020-06-09 2024-01-04 Pfizer Inc. Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
CA3241470A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
US3857939A (en) * 1971-08-18 1974-12-31 Hoffmann La Roche Chewable sodium-free vitamin c tablets
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
DE69005768T2 (de) * 1989-04-18 1994-04-28 Taisho Pharma Co Ltd Verfahren zur herstellung einer geschmacksmaskiertenzubereitung.
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
KR0168715B1 (ko) * 1992-11-30 1999-01-15 밋첼 아이. 커시너 맛을 차단하는 약제학적 조성물

Also Published As

Publication number Publication date
NO943341L (no) 1994-09-09
FI944165A0 (fi) 1994-09-09
AU3648493A (en) 1993-10-05
AU670428B2 (en) 1996-07-18
WO1993017667A1 (en) 1993-09-16
CA2131547A1 (en) 1993-09-16
JPH06116138A (ja) 1994-04-26
JP3265680B2 (ja) 2002-03-11
EP0630233B1 (en) 1996-09-25
EP0630233A1 (en) 1994-12-28
DE69305069T2 (de) 1997-03-13
DE69305069D1 (de) 1996-10-31
CA2131547C (en) 2002-02-12
MXPA93001352A (es) 2005-02-22
ATE143258T1 (de) 1996-10-15
ES2095043T3 (es) 1997-02-01
NO943341D0 (no) 1994-09-09
US5707646A (en) 1998-01-13
FI109657B (fi) 2002-09-30
FI944165A (fi) 1994-09-09

Similar Documents

Publication Publication Date Title
NO943341L (no) Sammensetninger for orale preparater
KR910011896A (ko) 신규한 글리코펩티드 유도체
AU640137B2 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them
GR3035414T3 (en) Novel imidazole derivatives, their preparation and therapeutic applications.
HUP9903536A2 (hu) Bázikus anyaggal stabilizált gyógyászati készítmények
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
NO942155D0 (no) Legemiddelformuleringer for parenteral anvendelse
NO952321D0 (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
KR880004808A (ko) 항신생 활성을 갖는 제약 조성물
MY101784A (en) Novel pharmacological compounds
TR199701294T1 (xx) Amoksisilin ve klavulanik asitten olu�an terkip.
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
KR870008824A (ko) 디플루오로할로메톡시페닐 유도체 및 그것을 유효성분으로 함유하는 살비제(殺碑制)
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
KR850002377A (ko) 살충제 조성물
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
MX9203100A (es) Nuevos peptidos, su preparacion y su aplicacion.
KR920701220A (ko) 신규의 복핵 백금 착체 및 이를 유효성분으로하는 항종양제
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
KR900009675A (ko) 신규 백금 착화합물
KR900016156A (ko) 퀴녹살린 유도체 및 궤양치료제
IE780981L (en) 6-(substituted amino)-penam compounds
AU2096688A (en) Improvements in or relating to leukotriene antagonists
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물

Legal Events

Date Code Title Description
MK1K Patent expired